- Validity of laboratory-based surveillance for detection of respiratory syncytial virus seasonsChristian Hampp
Division of Epidemiology I, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services, Silver Spring, MD 20993, USA
Am J Epidemiol 177:841-51. 2013..The 10% MPP with the added requirement of at least 5 positive tests is a valid method for identifying clinically significant RSV seasons across geographically diverse states...
- Cost-effectiveness of respiratory syncytial virus prophylaxis in various indicationsChristian Hampp
Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
Arch Pediatr Adolesc Med 165:498-505. 2011..To evaluate the cost-effectiveness of immunoprophylaxis against respiratory syncytial virus (RSV) infections with palivizumab based on actual cost and observed incidence rates in various pediatric risk groups...